NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
4.21
Dollar change
-0.62
Percentage change
-12.84
%
Index- P/E- EPS (ttm)-44.81 Insider Own2.26% Shs Outstand2.83M Perf Week57.68%
Market Cap12.14M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.82M Perf Month152.10%
Enterprise Value19.38M PEG- EPS next Q- Inst Own23.71% Short Float5.91% Perf Quarter192.36%
Income-42.38M P/S173.43 EPS this Y- Inst Trans0.62% Short Ratio0.05 Perf Half Y-35.51%
Sales0.07M P/B- EPS next Y- ROA-263.55% Short Interest0.17M Perf YTD-63.96%
Book/sh-3.43 P/C3.09 EPS next 5Y- ROE-388.03% 52W Range0.85 - 124.80 Perf Year-91.79%
Cash/sh1.36 P/FCF- EPS past 3/5Y-15.48% 12.70% ROIC- 52W High-96.63% Perf 3Y-97.20%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-84.00% - Gross Margin-6754.50% 52W Low395.29% Perf 5Y-98.35%
Dividend TTM- EV/Sales276.86 EPS Y/Y TTM25.89% Oper. Margin-40901.24% Volatility53.08% 28.91% Perf 10Y-
Dividend Ex-Date- Quick Ratio0.34 Sales Y/Y TTM663.82% Profit Margin-63194.11% RSI (14)56.64 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio0.34 EPS Q/Q91.51% SMA2039.77% Beta1.00 Target Price2.00
Payout- Debt/Eq- Sales Q/Q194.81% SMA50124.10% Rel Volume0.74 Prev Close4.83
Employees14 LT Debt/Eq- EarningsMay 19 AMC SMA200-68.28% Avg Volume3.14M Price4.21
IPOJan 25, 2018 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume2,314,677 Change-12.84%
Date Action Analyst Rating Change Price Target Change
Nov-18-24Downgrade H.C. Wainwright Buy → Neutral $12 → $2
Mar-01-21Initiated Northland Capital Outperform $10
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Jun-18-25 02:04PM
08:32AM
Jun-17-25 02:55PM
May-19-25 05:30PM
Apr-10-25 07:00AM
03:11PM Loading…
Mar-20-25 03:11PM
10:24AM
07:00AM
Feb-26-25 07:00AM
Feb-24-25 07:00AM
Feb-05-25 07:00AM
Jan-28-25 04:05PM
Jan-15-25 07:00AM
Jan-06-25 07:00AM
Dec-06-24 08:00AM
08:00AM Loading…
Nov-25-24 08:00AM
Nov-23-24 07:05AM
Nov-22-24 07:00AM
Nov-19-24 06:15AM
Nov-18-24 07:38AM
Nov-15-24 01:15PM
07:00AM
Nov-13-24 02:17AM
Nov-12-24 05:45PM
04:05PM
Nov-07-24 07:00AM
Oct-23-24 07:00AM
Oct-16-24 07:00AM
Oct-14-24 09:55AM
Oct-09-24 06:13PM
07:00AM Loading…
Oct-01-24 07:00AM
Sep-27-24 08:30AM
Sep-26-24 07:00AM
Sep-09-24 06:53AM
03:00AM
Sep-05-24 07:00AM
Sep-03-24 07:00AM
Aug-23-24 11:42AM
Aug-21-24 09:29AM
Aug-20-24 05:09PM
Aug-15-24 12:00PM
Aug-13-24 07:00AM
Aug-12-24 05:30PM
04:05PM
Aug-08-24 07:00AM
Aug-07-24 05:11PM
08:00AM
Jul-30-24 08:00AM
Jul-23-24 07:00AM
Jul-01-24 06:50AM
Jun-28-24 08:00AM
May-23-24 06:00AM
May-20-24 12:00PM
May-16-24 03:07AM
May-15-24 08:55PM
04:01PM
May-14-24 07:00AM
May-10-24 06:31AM
Apr-25-24 07:00AM
Apr-09-24 09:29AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Mar-27-24 11:28AM
09:57AM
Mar-19-24 08:50AM
06:41AM
Mar-18-24 08:53PM
05:20PM
04:05PM
Mar-13-24 07:00AM
Mar-11-24 07:00AM
Mar-05-24 12:59PM
08:00AM
Mar-04-24 06:21PM
06:06PM
Feb-13-24 07:00AM
Jan-26-24 09:22AM
Jan-16-24 07:00AM
Dec-15-23 08:17AM
Nov-14-23 10:38AM
Nov-13-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 07:00AM
Oct-30-23 03:52PM
07:00AM
Oct-09-23 07:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-24-23 06:47PM
Aug-16-23 06:00AM
Aug-14-23 09:05AM
Aug-11-23 06:08AM
Aug-10-23 04:05PM
Aug-09-23 08:00AM
Aug-07-23 08:00AM
Aug-03-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 09:00AM
Jun-01-23 08:00AM
May-12-23 06:04AM
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rowe Michael MChief Executive OfficerAug 28 '24Buy0.5227,07114,077109,998Aug 28 08:01 PM
Rowe Michael MChief Executive OfficerAug 26 '24Buy0.5750,00028,50082,927Aug 27 01:06 PM
Grant Stuart M.10% OwnerJul 02 '24Buy0.661,515,1511,000,00010,914,153Jul 03 03:18 PM